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Microchimerism and Skin Disease: 
True-True Unrelated?
Anita C. Gilliam1
Microchimerism, the stable presence of foreign cells in an individual, may result 
from trafficking during pregnancy or from organ or hematopoietic transplan-
tation, and has been hypothesized to cause autoimmunity and certain skin 
diseases. Yet microchimeric cells are found in normal individuals and may be 
important to tissue repair. Thus microchimerism may be common, and find-
ing microchimeric cells in diseased as well as normal tissue may be a “true-true 
unrelated” situation.
Journal of Investigative Dermatology (2006) 126, 239–241. doi:10.1038/sj.jid.5700061
Microchimerism and Cell Trafficking 
During Pregnancy
The word ‘chimera’ comes from a 
mythological animal that is a com-
bination of lion, goat and snake. In 
modern biology, ‘microchimerism’ is 
the stable presence of low numbers 
of foreign cells in an individual. For 
instance, approximately 8% of identi-
cal twins are chimeric for each other’s 
leukocytes because of a shared blood 
supply in utero. In single pregnancies, 
the placenta allows passage of mater-
nal and fetal cells in both directions, 
which explains how fetal and maternal 
microchimerism can occur after preg-
nancy. Cord blood samples collected 
for transplantation contain up to 20% 
maternal cells by in situ hybridiza-
tion and up to 40% maternal cells by 
PCR (Lo et al., 1996). These foreign 
cells can persist in both mother and 
child, giving rise to microchimerism. 
Bianchi et al. reported that CD34+ and 
CD34+CD38+ fetal cells were present 
in maternal circulation up to 27 years 
after pregnancy (Bianchi et al., 1996). 
This microchimerism is more likely 
when the fetus is HLA compatible 
with the mother. Fetal microchimerism 
is not as well characterized but is an 
intriguing new area of investigation.
What types of cells are seen in 
microchimerism due to maternal–fetal 
exchange via the placenta? Highly dif-
ferentiated cells such as fetal nucleated 
erythrocytes or placental trophoblasts 
in maternal blood are a useful marker 
of placental health. When an increased 
number of nucleated erythrocytes and 
trophoblasts are present in maternal 
circulation, abnormal placental bar-
rier function such as in preeclampsia 
or fetal aneuploidy can also be present 
(Bianchi, 2000). These differentiated 
cells do not survive long in maternal 
circulation. However, fetal stem and 
progenitor cells can proliferate, differ-
entiate and travel to various maternal 
tissues. Cord blood is an important 
source of fetal stem cells, which are 
known to have a mobile and plastic 
phenotype, and it is the likely source of 
cells in maternal microchimerism. Fetal 
hematopoietic stem cells, and presum-
ably their progeny T and B lympho-
cytes, monocytes and NK cells, have 
been demonstrated in maternal circula-
tion and tissue. Similarly, maternal stem 
cells can survive and proliferate in the 
tissues of offspring because of the two-
way traffic of cells via the placenta.
Stem Cells
Multiple types of stem cells have been 
identified, and the list of stem cells in 
adult individuals continues to expand. 
Adult bone marrow contains hemato-
poietic stem cells, mesenchymal stem 
cells and multipotent adult progenitor 
cells that can form cells of all lineages: 
ectodermal, mesenchymal and endo-
dermal (Grove et al., 2004).
Many studies support the concept of 
transdifferentiation — the reprogram-
ming of stem cells to differentiate into 
multiple different cell types appropri-
ate to their local environments (Alonso 
and Fuchs, 2003). Thus the mater-
nal–fetal exchange via the placenta, 
coupled with the enormous potential 
of stem cells to produce a variety of 
cell types, might produce a microchi-
merism of not only hematopoietic cells 
but also cells of all possible lineages, 
including skin cells.
Microchimerism and Transplantation
The study of microchimerism in trans-
plantation biology allows manipula-
tion of the variables and has led to 
some remarkable findings. Recipients 
of transplanted hematopoietic cells 
remain chimeric for donor and recipi-
ent immune cells for a long time after 
transplantation. Because bone mar-
row stem cells are diverse and plastic, 
other tissues also become chimeric for 
donor and recipient after bone marrow 
transplantation. Bone marrow-derived 
cells can contribute to tissue repair 
(skeletal muscle, cardiac muscle, liver, 
lung, kidney, central nervous system). 
Bone marrow-derived Y chromosome-
positive keratin-positive cells can be 
found in skin of female recipients of 
bone marrow transplanted from male 
donors (Grove et al., 2004).
Microchimerism also occurs in recip-
ients of solid organ transplants (lung, 
liver and kidney). Starzl and colleagues 
proposed that organ engraftment is a 
form of partial tolerance that is depen-
dent on leukocyte chimerism generated 
by ‘passenger leukocytes’ and stem 
cells in solid organ grafts (Starzl, 2004). 
In these situations, the microchimerism 
studied is of leukocytes, transmitted 
to the recipient via transplantation of 
passenger leukocytes in a solid organ 
such as intestine, lung, liver or kid-
ney. Anderson and Matzinger studied 
microchimerism produced by passen-
ger leukocytes in skin grafts in mice and 
found that the outcomes varied depend-
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ing mainly on the recipients’ immuno-
logical maturity and on the antigenic 
differences. They concluded that donor 
cells could be either tolerogenic or 
immunogenic, depending on the condi-
tions (Anderson and Matzinger, 2001). 
Therefore, the rules for the sequelae of 
microchimerism due to transplantation 
in humans are complex and are still 
being defined.
Microchimerism and Autoimmunity
What are the consequences of micro-
chimerism? It has been proposed that 
microchimerism may lead to auto-
immune disease in some individuals 
with a permissive genetic makeup. 
Autoimmune diseases in recipients 
of transplanted hematopoietic cells 
are well known. These include graft-
versus-host disease, which can 
be lupus-like or scleroderma-like, 
Sjögren’s syndrome, primary biliary 
cirrhosis, myositis, myasthenia gravis, 
hyper- and hypothyroidism and auto-
immune cytopenias (thrombocytope-
nia, leukopenia, neutropenia). Disease 
in transplant recipients resembles that 
in individuals with the correspond-
ing primary autoimmune diseases. 
The dysregulation of tolerance in the 
transplant recipient is thought to allow 
development of autoreactive T-cell 
clones, leading to autoimmune dis-
ease. Whether this results from micro-
chimerism or simply from immuno-
compromise is not known.
The best-studied example of 
immune-cell microchimerism as a 
possible factor in primary autoim-
mune disease is scleroderma, which 
has a peak incidence in women after 
the childbearing years. Women with 
scleroderma are more likely than 
matched control subjects to have had 
an HLA-compatible fetus, and Y chro-
mosome-positive cells can be found in 
fibrotic maternal tissue of women with 
scleroderma many years after delivery 
of a male baby (Artlett, 2005). Fetal 
microchimerism has been proposed 
as an explanation for scleroderma in 
males and children. This hypothesis for 
microchimerism as a cause of sclero-
derma is still in debate (Adams and 
Nelson, 2004).
Studies on other autoimmune disor-
ders and in normal individuals have led 
to conflicting data. For instance, other 
autoimmune diseases with female pre-
dominance and a later onset do not 
have demonstrable microchimerism 
(Sjögren syndrome, primary biliary 
cirrhosis). Also, microchimerism can 
be shown in normal individuals and 
in non-autoimmune diseases such as 
infectious hepatitis and cervical can-
cer (Johnson and Bianchi, 2004). A 
case control study of individuals with 
a variety of connective tissue diseases 
led to the conclusion that microchime-
rism was common in all individuals, 
including normal ones (Gannage et 
al., 2002). Bianchi, who first reported 
microchimerism in humans, concludes 
that multiple factors may determine 
whether microchimerism is a cause of 
disease: presence of foreign cells not 
only in blood but also in diseased tis-
sue; tissue type; disease type; history 
of pregnancy; and immune status are 
all important (Johnson and Bianchi, 
2004). To date, the connection between 
microchimerism and disease has not 
yet been definitively made. In fact, it 
has also been suggested that fetal cells 
may provide a renewable source of 
stem cells that can help with repair of 
maternal tissues, a positive rather than 
a negative outcome of microchime-
rism. One hypothesis is that stem cells 
may migrate to sites of inflammation 
and differentiate into cells that partici-
pate in repair. Thus, finding microchi-
meric cells in diseased tissue does not 
necessarily mean they were responsible 
for the initial injury.
Microchimerism and Skin Disease
In addition to scleroderma, other 
examples of microchimerism and skin 
disease due to the two-way traffic 
between mother and fetus have been 
proposed. For instance, it has been 
suggested that fetal cells in the mater-
nal circulation produce the eruptions 
associated with pregnancy, such as 
pruritic urticarial papules and plaques. 
Pemphigoid gestationis is thought to be 
an immune reaction to the father’s his-
tocompatibility antigens on fetal cells 
in maternal tissue. Erythema toxicum 
neonatorum, which occurs in the first 
few days postpartum, may be a mild 
graft-versus-host disease-like reaction 
to maternal cells in the newborn.
A new paradigm — the presence of 
cells other than leukocytes in micro-
chimerism as a possible factor in skin 
disease — is explored in the article 
by Khosrotehrani et al. in this issue 
(2006). The authors identified mater-
nally derived cytokeratin-positive cells 
in archival paraffin-embedded sections 
of the skin of 11 of 12 male children 
with pityriasis lichenoides by fluores-
cent in situ hybridization with X and 
Y chromosome-specific probes. These 
maternally derived cells were also 
present in biopsies of skin from male 
control subjects without skin disease, 
but with a lower frequency (4 of 7) and 
density (approximately 20-fold lower 
in pityriasis lichenoides patients than 
in normal subjects).
The search for foreign cells in skin 
disorders has produced conflicting 
data. Inherent in these experiments are 
the technical difficulties of fluorescent 
in situ hybridization or PCR analysis in 
archived specimens. Background can 
be high and interpretation difficult. 
Often the sequences of interest are 
also found in normal control subjects. 
For instance, women with lichen scle-
rosis with and without squamous-cell 
carcinoma, vulvar Paget’s disease, and 
normal vulvar skin who had male child-
ren were no different when Y chromo-
some sequences were evaluated by 
PCR in paraffin-embedded sections.
In summary, microchimerism not 
only of leukocytes but also of other 
cell types may be a common event 
in both normal and diseased tissues, 
a "true-true unrelated" situation. Host 
reaction to microchimerism as a cause 
of skin disease has not yet been defini-
tively demonstrated.
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Nuclear hormone receptors are tran-
scription factors that regulate the 
expression of target genes by binding to 
regulatory DNA sequences and interact-
ing with co-regulatory protein complex-
es. A large molecular family of these 
receptors has been identified by homo-
logy searches. Soon after the sequences 
became available, individual receptors 
were characterized for their tissue distri-
bution, ligand identity, patterns of target 
gene activation, and interaction with 
co-regulatory proteins. To better under-
stand their physiological roles, individ-
ual receptors were tested in genetic ani-
mal models of loss and gain of function.
In this fashion, peroxisome proli-
ferator-activated receptor-α (PPARα) was 
found to be a nuclear hormone recep-
tor that is activated by fatty acid-derived 
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(P)PARsing Epidermal Development
Sandrine Dubrac1 and Matthias Schmuth1
Overexpression of PPAR-α, a developmental transcription factor important in 
epidermal embryogenesis, in basal keratinocytes causes epidermal thinning 
when activated constitutively during development, but not if activated in adults; 
and lack of PPAR-α transiently delays stratum corneum formation within a win-
dow late in epidermal development (day 18.5 to birth). In contrast, pharmaco-
logic activation of PPAR-α inhibits proliferation and induces differentiation in 
mouse epidermis regardless of developmental stage. Thus, PPAR-α is an impor-
tant regulator of epidermal homeostasis.
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ligands. Since Issemann and Green 
cloned mouse PPARα in 1990 and Sher 
et al. cloned its human homologue in 
1993 (Issemann and Green, 1990; Sher 
et al., 1993), several groups have gener-
ated mouse models of PPARα deficiency. 
Such animals displayed abnormal lipid 
and xenobiotic metabolism in the liver, 
heart, muscle, and kidney, indicating 
a role of PPARα in fatty acid oxidation 
and detoxification of xenobiotic com-
pounds. Although PPARα was originally 
evaluated for its systemic activities, its 
expression was soon also noted in skin.
PPARα is present in both epidermis 
and dermis beginning at day 13.5 of 
development. Yet shortly after birth it 
becomes undetectable in the interfol-
licular epidermis, although expression 
persists in the hair follicles (Michalik 
et al., 2001). Injury to adult murine 
skin, such as hair plucking, induces 
re-expression of PPARα in the adult 
interfollicular epidermis, and re-expres-
sion can also be observed in the edges 
of full-thickness wounds. Conversely, 
in PPARα-deficient mice, the early 
phase of wound healing is delayed, 
and this delay is retained when the 
deficiency is targeted to the epidermis 
only and not to the dermis (Michalik 
et al., 2005). In pups lacking PPARα, a 
delay in stratum corneum formation is 
observed between day 18.5 of epider-
mal development and birth (Schmuth et 
al., 2002), whereas in PPARα-deficient 
adults, only a modest decrease in the 
expression of involucrin, loricrin, and 
filaggrin persists. This indicates that 
other mediators can compensate for 
the absence of PPARα; that is, there is 
redundancy (Komuves et al., 2000).
In this issue, Gonzalez et al. (2006) 
report on the skin phenotype of trans-
genic mice constitutively overexpress-
ing PPARα in the epidermis. These mice 
die within 2 days after birth, presum-
ably because of abnormal development 
of the tongue and mammary gland epi-
thelia; overexpression of PPARα also 
results in epidermal thinning and sparse 
fur in these animals, which could con-
tribute to the lethality. Importantly, cor-
responding to the transient effects of 
PPARα deficiency on developing epi-
dermis, PPARα overexpression exerts 
its effects only during a developmental 
window; that is, after birth it does not 
cause the abnormalities.
Consequences of a gain of PPARα 
function have previously been stud-
ied using pharmacologic activators. In 
explants of developing rat epidermis, the 
expression of proteins required for epi-
dermal differentiation (filaggrin, loricrin, 
involucrin) was stimulated by the PPARα 
agonist farnesol (Hanley et al., 1997). In 
contrast to the VP16PPAR-α bitransgen-
ic mice reported here (Gonzales et al., 
2006), there was a concomitant induc-
tion of the granular layer. These differ-
ences could be explained by differences 
between in vitro and in vivo experimen-
tal systems and by differences in the tim-
ing of the PPARα signal. Nevertheless, 
in adult mice, pharmacologic activation 
of PPARα induces epidermal differentia-
tion, inhibits proliferation, and increases 
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